test

James Silverman

@Opaleye Management Inc.

Latest period2024 - Q3ReportedManaged Assets$599.558MTotal holdings44
Assets growth rate37%Assets growth rate (2-Q avg)16.19%Continuous growth in asset value1 quarters

Portfolio positions

This chart displays the top 10 holdings in Opaleye Management Inc.'s 2024 - Q3 portfolio, based on their 13F SEC filing, out of a total of 44 positions.

Assets under management

The assets under management (AUM) of Opaleye Management Inc. over the past 10 years (40 quarters) show continuous growth in total asset value over the last 1 quarters. As of the latest 13F SEC filing for 2024 - Q3, they manage 599.558M in assets, with a quarterly growth rate of 37% and a 2-quarter average growth rate of 16.19%. The portfolio is managed by James Silverman, and others.

Portfolio holdings

CurrentNew PositionIncreasedDecreasedExited
InvestmentPortfolio %Reported Value
TARAProtara Therapeutics Inc
Recent Activity
Decreased -27.04%
0.52%
$3.077M
1.681M shares@ $1.84 avg price
RZLTRezolute Inc
Recent Activity
New Position
0.38%
$2.263M
466,563 shares@ $4.86 avg price
CPRXCatalyst Pharmaceuticals Inc
Recent Activity
Decreased -82.42%
0.38%
$2.236M
112,500 shares@ $19.88 avg price
ABCLAbcellera Biologics Inc
Recent Activity
Increased 300%
0.35%
$2.08M
800,000 shares@ $2.6 avg price
LYELLyell Immunopharma Inc
Recent Activity
Decreased -16.46%
0.33%
$1.925M
1.395M shares@ $1.38 avg price
ALLKAllakos Inc
Recent Activity
Decreased -13.39%
0.27%
$1.573M
2.408M shares@ $0.66 avg price
RLMDRelmada Therapeutics Inc
Recent Activity
Decreased -20%
0.26%
$1.555M
480,000 shares@ $3.24 avg price
PEPGPepgen Inc
Recent Activity
New Position
0.26%
$1.532M
179,200 shares@ $8.56 avg price
RVNCRevance Therapeutics Inc
Recent Activity
New Position
0.24%
$1.427M
275,000 shares@ $5.19 avg price
SYRSSyros Pharmaceuticals Inc
Recent Activity
Decreased -24.32%
0.24%
$1.408M
654,943 shares@ $2.15 avg price